16 May 2024
Latham Advises on Pacira BioSciences, Inc. in Pricing of US$250 Million in Convertible Senior Notes
Advising firms
Deal team
11 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Greg Rodgers Lead | Latham & Watkins LLP | Partner | capital markets | Los Angeles/New York |
| Nathan Ajiashvili | Latham & Watkins LLP | Partner | capital markets | New York |
| Ryan Gold | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Roger Yarett | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Andrew Bentz | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Richard Dacher | Latham & Watkins LLP | Associate | capital markets | Not stated |
| Eric Rice | Latham & Watkins LLP | Partner | derivatives | New York |
| Shawn Noh | Latham & Watkins LLP | Associate | derivatives | Not stated |
| Henry Lin | Latham & Watkins LLP | Associate | derivatives | Not stated |
| Elena Romanova | Latham & Watkins LLP | Partner | tax | New York |
| James Aldred | Latham & Watkins LLP | Associate | tax | Not stated |
8 more lawyers on this deal. Register free to see the full deal team, with seniority, practice and office.
REGISTER FREE SIGN INWant co-counsel patterns, repeat clients and alerts when these firms land their next deal? Get Pro.
Stated terms
- Stated value
- USD 250m (US$250 million)
- What the figure measures
- Issue size
- Client
- Not stated
- Counterparties
- Pacira BioSciences, Inc. (Issuer)